• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chronic myeloid leukemia--advances in biology and new approaches to treatment.

作者信息

Goldman John M, Melo Junia V

机构信息

Department of Haematology, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom.

出版信息

N Engl J Med. 2003 Oct 9;349(15):1451-64. doi: 10.1056/NEJMra020777.

DOI:10.1056/NEJMra020777
PMID:14534339
Abstract
摘要

相似文献

1
Chronic myeloid leukemia--advances in biology and new approaches to treatment.慢性髓性白血病——生物学进展与新的治疗方法
N Engl J Med. 2003 Oct 9;349(15):1451-64. doi: 10.1056/NEJMra020777.
2
[Molecular signal transduction inhibitor for treatment of chronic myeloid leukemia].用于治疗慢性髓性白血病的分子信号转导抑制剂
Zhonghua Yi Xue Za Zhi. 2005 Apr 27;85(16):1082-4.
3
[Chronic myelogenous leukaemia: recent progress in biology and therapeutic strategies].
Bull Cancer. 2005 Jan;92(1):75-82.
4
[Treatment strategies for chronic myeloid leukemia].
Rinsho Ketsueki. 2005 Jan;46(1):1-6.
5
Roots of clinical resistance to STI-571 cancer therapy.对STI-571癌症治疗产生临床耐药性的根源。
Science. 2001 Sep 21;293(5538):2163. doi: 10.1126/science.293.5538.2163a.
6
Minimal residual disease in chronic myeloid leukemia.慢性髓性白血病中的微小残留病
N Engl J Med. 2003 Oct 9;349(15):1399-401. doi: 10.1056/NEJMp038130.
7
Recent advancements in the treatment of chronic myelogenous leukemia.慢性粒细胞白血病治疗的最新进展
Annu Rev Med. 2002;53:369-81. doi: 10.1146/annurev.med.53.082901.103853.
8
Roots of clinical resistance to STI-571 cancer therapy.对STI-571癌症治疗产生临床耐药性的根源。
Science. 2001 Sep 21;293(5538):2163.
9
Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.一名同时表达p190（BCR-ABL）癌蛋白和JAK2V617F突变的慢性髓性白血病患者对伊马替尼的反应
Leuk Res. 2010 Jan;34(1):e27-9. doi: 10.1016/j.leukres.2009.08.009. Epub 2009 Sep 12.
10
Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation.伊马替尼治疗异基因移植后慢性髓性白血病复发患者的分子和嵌合反应的长期耐久性
Eur J Haematol. 2011 Aug;87(2):182-5. doi: 10.1111/j.1600-0609.2011.01628.x.

引用本文的文献

1
Regulation of Tetraspanin CD63 in Chronic Myeloid Leukemia (CML): Single-Cell Analysis of Asymmetric Hematopoietic Stem Cell Division Genes.慢性髓性白血病（CML）中四跨膜蛋白CD63的调控：不对称造血干细胞分裂基因的单细胞分析
Bioengineering (Basel). 2025 Jul 31;12(8):830. doi: 10.3390/bioengineering12080830.
2
Surgical management of giant splenomegaly in chronic myeloid leukemia: a challenging splenectomy case.慢性髓性白血病巨大脾肿大的外科治疗：一例具有挑战性的脾切除术病例
J Surg Case Rep. 2025 Jul 8;2025(7):rjaf485. doi: 10.1093/jscr/rjaf485. eCollection 2025 Jul.
3
Unilateral sudden hearing loss as the first presenting symptom of chronic myeloid leukemia: a case report and literature review.
单侧突发听力损失作为慢性髓性白血病的首发症状：一例报告及文献综述
Front Oncol. 2025 May 27;15:1579765. doi: 10.3389/fonc.2025.1579765. eCollection 2025.
4
Role of microRNA-486-5p as Biomarker Response in Cell Line K562 of Chronic Myeloid Leukemia.微小RNA-486-5p在慢性髓性白血病K562细胞系中作为生物标志物反应的作用
Asian Pac J Cancer Prev. 2025 Apr 1;26(4):1181-1187. doi: 10.31557/APJCP.2025.26.4.1181.
5
Phyto-chemistry and Therapeutic Potential of Natural Flavonoid Naringin: A Consolidated Review.天然黄酮类化合物柚皮苷的植物化学与治疗潜力：综合综述
Chin J Integr Med. 2025 Feb 25. doi: 10.1007/s11655-025-3826-9.
6
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.从血液系统恶性肿瘤中p53的调控到去调控：对诊断、预后和治疗的影响
Biomark Res. 2024 Nov 14;12(1):137. doi: 10.1186/s40364-024-00676-9.
7
Advancements in the impact of human microbiota and probiotics on leukemia.人类微生物群和益生菌对白血病影响的研究进展。
Front Microbiol. 2024 Jul 3;15:1423838. doi: 10.3389/fmicb.2024.1423838. eCollection 2024.
8
Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib.抑制 LATS 激酶可降低肿瘤生成能力，并增加人慢性髓性白血病细胞对伊马替尼的敏感性。
Sci Rep. 2024 Feb 18;14(1):3993. doi: 10.1038/s41598-024-54728-z.
9
Leukemia Cutis-The Current View on Pathogenesis, Diagnosis, and Treatment.皮肤白血病——关于发病机制、诊断和治疗的当前观点
Cancers (Basel). 2023 Nov 13;15(22):5393. doi: 10.3390/cancers15225393.
10
[Application and clinical significance of intercellular proximity labeling technique in chronic myelogenous leukemia].[细胞间邻近标记技术在慢性粒细胞白血病中的应用及临床意义]
Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):543-549. doi: 10.3760/cma.j.issn.0253-2727.2023.07.003.